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ABSTRACT
Introduction: Exploration in the field of epigenetics has revealed the diverse roles of the protein
arginine methyltransferase (PRMT) family of proteins in multiple disease states. These findings have led
to the development of specific inhibitors and discovery of several new classes of drugs with potential to
treat both benign and malignant conditions.
Areas covered: We provide an overview on the role of PRMT enzymes in healthy and malignant cells,
highlighting the role of arginine methylation in specific pathways relevant to cancer pathogenesis.
Additionally, we describe structure and catalytic activity of PRMT and discuss the mechanisms of action
of novel small molecule inhibitors of specific members of the arginine methyltransferase family.
Expert opinion: As the field of PRMT biology advances, it’s becoming clear that this class of enzymes is
highly relevant to maintaining normal physiologic processes as well and disease pathogenesis. We
discuss the potential impact of PRMT inhibitors as a broad class of drugs, including the pleiotropic
effects, off target effects the need for more detailed PRMT-centric interactomes, and finally, the
potential for targeting this class of enzymes in clinical development of experimental therapeutics for
cancer.
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1. Introduction
Virtually every nucleated cell of the human body contains an
identical copy of the human genome. While each cell is intrin-
sically similar, the ability of a cell to differentiate and specialize
is essential to normal embryonic development and survival of
the organism. Our genome encodes the full repertoire of
genes shared by all humans, but it is the coordinated expres-
sion of specified sets of genes that determines the differentia-
tion and commitment of a cell to a distinct lineage. This
controlled expression is regulated not by direct changes to
the DNA sequence, but by a complex assortment of post-
translational modifications that alter nucleoprotein–DNA inter-
actions and ultimately drive changes in gene expression. The
field of epigenetics studies chemical modifications of DNA and
chromatin that set a dynamic stage to affect cellular pheno-
type, without changing genotype [1].
The structural unit of the chromosome provides a platform
for packaging approximately 1.8 m of DNA into the nucleus no
more than 10 μm in diameter. DNA wound about the histone
structural proteins form the nucleoprotein supra-structure
known as chromatin. Four histone proteins (H2A, H2B, H3,
and H4, and associated isoforms) assemble into an octamer
forming a core about which nuclear DNA is wound in ~150
base pair loops, forming the nucleosome. The dynamic
association between DNA and this histone core determines
the degree of accessibility of transcriptional machinery to DNA
and accounts for fine-tuned regulation of gene expression.
Chromatin structure ranges from tightly packed, condensed
heterochromatin to a more relaxed, open, euchromatin state.
The restricted availability of DNA in heterochromatin generally
correlates with more repressed transcriptional activity,
whereas a more loosely packed euchromatin state allows for
the binding of polymerase machinery, resulting in active tran-
scription. Covalent modifications of specific nucleotides and
histone amino acid residues are controlled by a wide array of
epigenetic enzymes [2].
Specific marks modified on DNA that are embedded in the
genetic code confer gene silencing. Induced by DNA methyl-
transferases (DNMTs), the methylation of the 5ʹ carbon of the
cytosine nucleotide largely takes place at CpG dinucleotides
and is associated with transcriptional repression [3]. Five-
hydroxymethyl cytosine (5hmc) has been identified as an
additional mark of gene silencing [4]. Believed to be an inter-
mediate step in cytosine demethylation, 5hmc is thought to
play a role in somatic reprogramming, hematopoiesis and
neuronal development [4–10]. Scientists continue to identify
novel epigenetic modifiers that read, write, and erase histone
post-translational marks (PTMs), thereby contributing to cova-
lent alterations collectively known as histone code. PTMs of
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histones include methylation or demethylation of lysine and/
or arginine within histone tails; acetylation or deacetylation of
lysine residues; ubiquitination of lysine molecules; and, finally,
phosphorylation of serine residues on histones [2]. As work
continues to identify the mechanism and nature of these
enzymes, their role in both normal cellular function and
pathologic disease states is becoming more clearly defined.
Small molecule inhibitors have successfully been designed to
target acetyl transferases, deacetylases, methylases and
demethylases, kinases, ubiquitin and SUMO ligases, as well as
ATP-dependent nucleosome remodeling enzymes.
Interest in developing novel classes of pharmacological
inhibitors continues to grow [11–13]. Protein arginine
methyltransferases (PRMTs) have more recently surfaced as
a family of highly conserved gene products that act as
major players in normal development and disease, position-
ing this class of enzymes as potentially intriguing therapeu-
tic targets [14,15]. In this review, we will address the
mechanism of action of these enzymes and the numerous
roles they play in normal cellular function and disease
pathophysiology. This review will also discuss current efforts
in the field of experimental therapeutics to inhibit the func-
tion of several classes of enzymes in this family. Finally, we
will conclude with an expert opinion on the relevance of
PRMTs as therapeutic targets in cancer.
2. Protein arginine methyltransferases
Arginine contains a guanidine group that provides five potential
hydrogen bond donors, promoting a high propensity to engage
in bonding with hydrogen bond acceptors. At physiological pH,
the guanidine group is protonated; however, it can also be
methylated at one or both of its terminal nitrogen atoms [16].
Three types of arginine methylation exist in the form of ω-NG-
monomethylarginine (MMA),ω-NG,NG–asymmetric dimethylargi-
nine (ADMA), and ω-NG,N’G–symmetric dimethylarginine (SDMA)
[17]. Unlike other PTMs, the covalent addition of a methyl group
does not change the overall charge of arginine, but rather its
addition is absorbed by resonance throughout the guanidinium
group. With little change in charge and pKa of the amino acid,
the main consequence of this modification is a change in shape.
Arginine dimethylation results in a bulkier side chain that elim-
inates hydrogen bond donor sites and increases overall hydro-
phobicity [18–20].
Each of the aforementioned histone modifications is cata-
lyzed by a family of nine PRMTs that can methylate both
histone and non-histone proteins. An overview of the types
of mammalian PRMTs and their associated functions is pro-
vided in Table 1. This family is classified into three subtypes,
based on the nature of the methylation reaction that is cata-
lyzed. Domain architecture of the PRMTs is summarized in
Figure 1. PRMTs type I, II, and III are able to generate ADMA,
SDMA, or MMA, respectively, as summarized in Figure 1.
PRMT1, the major type I enzyme, is responsible for driving
the majority of ADMA modifications. PRMT5, a type II enzyme,
drives the formation of SDMA marks (Figure 2) [17].
Furthermore, all PRMTs catalyze the production of MMA.
2.1 Type I PRMTs
Type I classification includes PRMT 1–4, 6, and 8 (Table 1,
Figure 1). They initiate reactions utilizing S-adenosyl-L-methio-
nine (SAM) as a cofactor that provides the methyl group and
catalyze the formation of a monomethylated arginine intermedi-
ate. All members of this class go on to utilize a second SAM
molecule to subsequently add an additionalmethyl group, finally
forming the characteristic asymmetric mark, ADMA.
Article highlights
● Here we provide a context for understanding the function of PRMT
enzymes as post-translational modifiers that play a role in target
protein function and epigenetic transcriptional regulation
● We describe members of the PRMT family and review structure/
function work that has led to development of novel pharmacologic
inhibitors.
● We provide an overview of the roles of arginine methylation in
driving cancer.
● We provide an overview of PRMT inhibitors with anti-cancer potential
that are being investigated in pre-clinical and emerging clinical
studies.
● Finally, we provide an expert opinion on PRMT targeting as a promis-
ing experimental therapeutic strategy for solid and blood cancers.
This box summarizes key points contained in the article.
Table 1. Overview of mammalian PRMTs.
Primary marks Function Knockout in vivo
PRMT1 H4R3me2a, H2AR3me2a Transcriptional activation Embryonic lethal
PRMT2 H3R8me2a, H4 site unknown Transcriptional regulation Knockout mice are viable
PRMT3 Non-histone RPS2 Ribosomal homeostasis Knockout mice are viable, but embryos are smaller than
wildtype
PRMT4/CARM1 H3R2me2a, H3R17me2a, H3R26me2a, non-
histone proteins
Transcriptional activation, mRNA
splicing
Knockout mice die shortly after birth
Embryos have defects in cellular development
PRMT5 H3R8me2s, H4R3me2s, H2AR3me2s Embryonic lethal
PRMT6 H3R2, H2AR92, H4R3me2a Transcriptional activation and
repression
Null mice are viable
PRMT7 H4R3, H2AR3, H3R2- monomethyl Male germline imprinting, DNA
repair
PRMT8 Unknown Brain specific function Embryonic and neuronal developmental defects in
zebrafish
PRMT9 Non-histone
SAP145/49
RNA splicing
Main marks associated with each PRMT and their functional consequences as well as in vivo phenotypes.
CARM1: co-activator-associated arginine methyltransferase 1; PRMT: protein arginine methyltransferases.
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2.1.1 PRMT1
PRMT1 was the first mammalian PRMT identified. PRTM1 is
responsible for over 80% of the steady-state levels of ADMA
in the proteome [21]. Substrate specificity of PRMT1 has
been shown to favor methylation of arginine residues with
neighboring glycines in the +1 or +2 position in a glycine-
and arginine-rich (GAR) motif [22,23]. Three-dimensional
structure has shown that PRMT1 exists as a homodimer
containing two active sites that allow for semi-processive
catalysis, in which the substrate remains bound to the
enzyme through monomethylation and subsequent
dimethylation prior to its release in an ADMA state [24,25].
PRMT1 exerts its epigenetic function by methylating histone
4 at arginine 3, generating the H4R3me2a mark.
Interestingly, the first five residues of H2A and H4 are
identical, and it is likely that most of the activities at H4R3
hold true for H2AR3 as well [26]. Physiological duplication of
this motif provides an efficient means of amplifying signals
at each of these sites. H4R3me2a has been characterized as
a mark associated with transcriptional activation and is
necessary for subsequent acetylation of H3 and H4 [27].
Additionally, PRMT1 has been shown to function as a coac-
tivator and facilitate the recruitment of tumor suppressor
proteins Yin Yang-1, p53, and runt-related transcription fac-
tor 1 to target gene promoters [28]. Inhibition of PRMT1
leads to cell death and furthermore, PRMT1 null mice are
embryonic lethal [27]. Inducible PRMT1 knockout in mouse
embryonic fibroblasts leads to induction of genomic instabil-
ity and cell cycle arrest, emphasizing the importance of
PRMT1 in the orchestration of controlled cell division [29].
PRMT1
PRMT2
PRMT3
PRMT4
PRMT5
PRMT6
PRMT7
PRMT8
PRMT9
Rossman fold
β-barrel
α-helix
Dimerization arm
Figure 1. Domain architecture of nine human PRMTs. Abbreviated: SH3, SH3 domain; ZnF, zinc finger motif; PH, Pleckstrin homology domain; TPR, tetratricopeptide
repeat.
Figure 2. Crystal structures of PRMTs. Conserved catalytic core are shown in grey (Rossman fold in light grey while β-barrel in dark grey). Cofactor or its analogs are
indicated in yellow, peptide is in green. TIM barrel domain of PRMT5 is colored in blue, the additional protein binding partner MEP50 is colored in orange. ‘Double E’
loop is colored in pink and ‘THW’ loop is in purple. PDB ID: PRMT1, 1OR8; PRMT3, 2FYT; PRMT4, 3B3M; PRMT5, 4GQB; PRMT6, 4HC4; PRMT7, 4M38; PRMT8, 4 × 41.
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2.1.2 PRMT2
Initially, because of its weak methyltransferase activity, PRMT2
was not believed to have enzymatic capabilities. However, it
was discovered to catalyze asymmetric demethylation of H3R8
and H4, although the exact nature of methylation of this
histone protein remains poorly characterized [30]. PRMT2 con-
tains an N-terminal Src homology 3 (SH3) domain that recog-
nizes proline-rich protein motifs and allows it to bind to the
N-terminal domain of PRMT8, in order to guide this enzyme to
substrate proteins [31,32]. The activity of PRMT2 has been
associated with enhanced gene transcription as it regulates
the androgen receptor and the estrogen receptor (ER) alpha,
the importance of which will be discussed below [33,34]. While
it has also been shown to inhibit the function of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) and
promote cellular apoptosis, PRMT2 knockout mice are viable
and exhibit normal development, suggesting that its function
is, to some extent, redundant [35,36].
2.1.3 PRMT3
Unlike other methyltransferases in the PRMT family, PRMT3 is
located exclusively in the cytosol and does not appear to
exhibit any known direct epigenetic functions. Rather, PRMT3
modifies a variety of non-histone substrates that control pro-
tein synthesis and the spliceosome. PRMT3 contains a zinc-
finger domain at its N-terminus (Figure 1), which allows it to
target the 40S ribosomal protein S2 (rpS2) and maintain ribo-
somal homeostasis within the cell (Figure 1) [37]. Mouse
embryos expressing a targeted mutant PRMT3 are smaller
than wildtype embryos. Despite this initial developmental
abnormality, all survive after birth and reach a normal size
during adulthood. Mice that are deficient in PRMT3 activity
also exhibit hypomethylated rpS2, confirming this is an in vivo
substrate for PRMT3 [38].
2.1.4 CARM1 (PRMT4)
PRMT4, also referred to as co-activator-associated arginine
methyltransferase 1 (CARM1), was the first PRMT shown to
coordinate transcriptional regulation [39]. By generating the
H3R17me2a and H3R26me2a marks, CARM1 works with sev-
eral other transcriptional factors including p53, NF-κB, peroxi-
some proliferator-activated receptor gamma, and c-Fos to
regulate target gene expression [17]. Numerous instances of
histone crosstalk have been linked to CARM1-associated
marks. CBP/P300-driven acetylation of H3K18 converts H3 to
an improved substrate for CARM1 and increases the rate of the
methyltransferase reaction [40]. It is hypothesized that by
neutralizing the positive charge of K18 the nucleophilic attack
on the sulfur-methyl bond of SAM becomes more favorable
[41]. It is also hypothesized that the H3R26me2a mark antag-
onizes methylation of H3K27 by the polycomb repressive
complex-2 by preventing enzymatic activity, but not binding
of the complex [42]. In addition to epigenetic regulation,
CARM1 also methylates transcription factors to coordinate
gene expression, splicing factors to couple transcription and
splicing processes, as well as RNA polymerase II [43]. Mice with
a CARM1 deletion illustrate the in vivo importance of this
enzyme. Mouse embryos show defects in development of T
lymphocytes, adipose tissue, chondrocytes, muscles, and lungs
[44–47]. Newborn mice are smaller than wildtype counterparts
and die shortly after birth [48].
2.1.5 PRMT6
PRMT6 has been shown to act as both a transcriptional acti-
vator and repressor. PRMT6 is located exclusively in the
nucleus and targets GAR sequences, asymmetrically methylat-
ing H3R2 as well as H4R3/H2AR3 [49]. The H3R2me2a mark
antagonizes the activating H3K4me3 mark, alluding to its role
as a transcriptional repressor [50]. Conversely, additional
reports demonstrate that PRMT6 has the capacity to act as a
co-activator of nuclear receptors, although the exact role of
this interaction is unclear [51]. While work is ongoing to con-
firm the true nature of PRMT6, in vivo experiments have
provided some insight. PRMT6 knockout mice are viable, but
embryonic fibroblasts from these mice undergo cell cycle
arrest and premature senescence [52]. Transgenic mice that
bear PRMT6 fused to the hormone-binding portion of the ER
that is inducible by tamoxifen exhibit a dysregulated pro-
inflammatory response and die within a 3-week period [53].
Ex vivo experiments demonstrate direct binding of PRMT6
with the RelA subunit of NF-κB, facilitating recruitment of
NF-κB to selected target promoters and NF-κB-regulated
gene expression [53].
2.1.6 PRMT8
PRMT8 is a unique member of this protein family as it is the
sole PRMT enzyme to be distributed in a tissue specific man-
ner, largely restricted to neurons. Despite displaying 80%
sequence homology and substrate preference with PRMT1,
PRMT8 contains a unique N-terminal myristoylation motif
that directs its location to the plasma membrane [54,55].
Interestingly, removal of this N-terminal region results in
increased enzymatic activity and mono- or asymmetric
dimethylation of H2A, H4, and myelin basic protein. In addi-
tion to a unique PTM, PRMT8 also possesses two proline-rich
regions, allowing it to bind SH3 domains, including that of
PRMT2 in vitro [32]. Deep sequencing of cancer genomes from
a variety of tissues shows that of all the PRMTs PRMT8 is most
frequently mutated, with over 100 mutations in the coding
region, with over 25,000 samples tested [56,57]. Recently, Lin
et al. demonstrated a critical role for PRMT8 for both embryo-
nic and neuronal development in a zebrafish model, high-
lighting its relevance in developmental biology in vertebrate
organisms [58].
2.2 Type II PRMT
2.2.1 PRMT5
PRMT5 is the sole type II PRMT enzyme and is largely respon-
sible for catalyzing the SDMA mark on a wide array of proteins
and histones within chromatin [59]. The tertiary structure of
PRMT5 assembles into a two-domain structure, forming a
triose-phosphate isomerase (TIM) barrel at the N-terminus.
Ultimately, PRMT5 forms a hetero-octomeric complex with
the methylosome protein 50 (MEP50), with PRMT5 tetramer
in the center, surrounded by four MEP50 molecules interacting
with the TIM barrel domains [60]. PRMT5 in complex with
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MEP50 shows enhanced capacity to drive its characteristic
type II SDMA marks on histones H2A, H3, and H4
(H2AR3me2s, H3R2me2s, H3R8me2s, and H4R3me2s) [60–63].
Interestingly, the PRMT5-MEP50 complex is capable of
methylating hypoacetylated histones more efficiently than
those that are hyperacetylated and of driving target gene
transcriptional activation via differential ratios of H4R3me2s/
H3R8me2s [64,65]. PRMT5 has been shown to play a pro-
survival role by methylating non-histone proteins as well.
The post-transcriptional methylation of P53 and the NF-κB
P65 subunit causes altered recruitment to target genes, lead-
ing to cell cycle progression, increased production of inflam-
matory cytokines, and cellular transformation [66–69].
PRMT5 is capable of methylating histones prior to incorpora-
tion into chromatin during embryogenesis and contributes
toward maintaining the undifferentiated and pluripotent state
of embryonic stem cells (ESCs) [70,71]. This role is essential for
ESCs as PRMT5 null mice die before birth [71]. PRMT5 condi-
tional knockout mice demonstrate aberrant erythroid differen-
tiation and thymocyte development as well as a loss of lineage
committed progenitor stem cells. Furthermore, PRMT5 null mice
exhibit stem cell exhaustion and ultimately succumb to bone
marrow failure. These effects appear to directly result from the
loss of PRMT5 methyltransferase activity, impaired cytokine sig-
naling, and increased p53 activity [72–74].
In addition to the role in cellular development and differ-
entiation, PRMT5 assembles into larger macromolecular com-
plexes including SWItch/sucrose non-Fermentable (SWI/SNF)
chromatin remodelers to silence numerous regulatory and
tumor suppressor genes via chromatin hypermethylation at
gene promoters [62]. PRMT5-mediated marks facilitate global
repression of genes that coordinate a variety of cellular func-
tions including RNA processing, transcriptional regulation, and
signal transduction pathways, all of which are relevant to
embryonic development and, when dysregulated, contribute
to oncogenesis and maintenance of the malignant phenotype
of a variety of solid tumor and blood cancers [75].
2.2.2 PRMT9
While initial studies have revealed the structure of PRMT9, the
enzyme has not been fully characterized, and multiple aspects
of the mechanisms that regulate its expression and cellular
function remain unknown. Like PRMT7, PRMT9 contains two
SAM binding domains; unlike other PRMTs, it possesses three
tetratricopeptide repeat motifs that facilitate protein–protein
interactions [54,56]. Mutant PRMT9 devoid of any of these
domains does not exhibit functional methyltransferase activity
[76]. Recent work by Yang et al. demonstrated that PRMT9 has
type II PRMT activity and symmetrically dimethylates spliceo-
some-associated proteins-SAP145 and SAP49 [77]. Methylation
of SAP145 creates a binding site for the Tudor domain con-
taining Survival of Motor Neuron protein. This modification
allows for the assembly of ribonucleoproteins and ultimately
facilitates mRNA splicing [77]. Work from the same group
showed that PRMT9 demonstrates relatively weak methylation
activity compared to common PRMT substrates and appears to
be relatively specific for the splicing factor [76]. It is interesting
that both type II PRMTs (PRMT5 and 9) are involved in the
post-translational methylation of RNA splicing machinery.
2.3 Type III PRMTs
2.3.1 PRMT7
Multiple recent reports have shown PRMT7 to catalyze both a
monomethyl and a symmetric dimethyl arginine mark in a
substrate-dependent manner, categorizing it as either a type
II or type III PRMT [78,79]. However, Zurita-Lopez and collea-
gues have shown that PRMT7 exclusively produces the MMA
mark on both histone and non-histone substrates in vitro
[80,81]. Like PRMT9, PRMT7 uniquely contains two SAM-bind-
ing motifs. Mouse PRMT7 has been implicated in histone
methylation, as was identified by Feng et al. via top-down
mass spectroscopy experiments that demonstrated its ability
to preferentially methylate-specific arginine residues sur-
rounded by lysines within RXR motifs of H2B, and support
formation of MMA [82]. This study identified specific substrate
motifs that PRMT7 recognizes. Authors speculate that methy-
lation of H2B by PRMT7 may play a role in transcriptional
regulation since the N-terminal region of H2B that contains
the motif recognized by PRMT7 plays a role in transcriptional
repression and also mediates histone methylation by the
methyltransferase Dot1 and facilitates telomeric silencing
[82,83].
PRMT7 has been implicated in a variety of functions.
Reports have shown that PRMT7 has a role in male germline
imprinted gene methylation through its interaction with CTCF
like/brother of the regulator of imprinted sites (CTCFL), a
regulator of imprinted gene expression [84]. In addition,
PRMT7 has been shown to negatively regulate the expression
of genes involved in DNA repair, with conflicting publications
showing a loss of PRMT7 to promote both resistance and
sensitivity to DNA damaging agents [85,86]. Several reports
have demonstrated a role for PRMT7 in the stemness of both
ESCs and satellite cells. In ESCs, PRMT7 indirectly regulates the
expression of pluripotent genes through a microRNA con-
trolled double-negative feedback loop [87]. Depletion of
PRMT7 in satellite cells results in premature senescence,
delayed activation of myogenic differentiation, and loss of
stem cell properties, resulting in the inability to engage in
tissue repair and defects in muscle regeneration [88]. This
regulation is mediated through PRMT7-dependent methyla-
tion of both the DNMT3b and Cdnk1a promoters [88]. Finally,
two separate studies have identified patients with autosomal
recessive developmental disorders related to PRMT7 muta-
tions. These genetic studies support the role of PRMT7 in
human intellectual and physical development [89,90].
2.4 Demethylation
Multiple experiments that investigated the turnover of argi-
nine methylation have shown it to be a particularly stable
mark [27,56,91]. However, dynamic changes in the appearance
and disappearance of the methylarginine mark raises the
question of whether it is in fact a reversible modification
[92,93] . While it is still unclear as to how exactly this mark is
removed, several mechanisms have arisen as potential candi-
dates for arginine demethylation: direct demethylation by
jumonji C domain-containing histone demethylases (JmjC
KDMs), or deimination by peptidyl arginine deiminases
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(PADIs) [94–96]. Ultimately, further investigation into the exact
mechanism of arginine demethylation is essential to under-
standing the functionality of this modification.
2.4.1 Peptidyl arginine deiminase activity
Peptidyl arginine deiminases (PADIs) are known to convert
arginine to citrulline through hydrolysis of the guanidinium
group [97]. It was hypothesized that PADIs also have the
capacity to convert methylated arginine in the same manner
to citrulline; however, structural analysis of the PADI active site
and in vitro assays with mono- and dimethylated peptides
suggest otherwise. Studies have shown that the demethylimi-
nation reaction occurs 100–10,000-fold slower for mono- or
dimethylated arginine residues than it does for unmethylated
arginine [19,97]. Thus, it appears that rather than a conversion
of methylated arginine to citrulline, citrullination works to
directly antagonize arginine methylation and that these two
modifications are mutually exclusive. As work continues to
investigate this family of enzymes, the kinetics of the modifi-
cation itself will continue to be explored and the stability of
the mark will be clarified. While citrullination does remove the
methyl-arginine mark, it is demethylimination and not true
demethylation,
2.4.2 JmjC oxygenases
The identity of a true arginine demethylase has been the topic
of controversy for several years. JMJD6 is a JmjC domain-
containing protein reported to demethylate both H3R2me2
and H4R3me2, both symmetric and asymmetric dimethylation
[98]. While JMJD6 is considered by some to be a true
demethylase, contradictory reports have surfaced since its
initial characterization. Structural studies by Hong et al. and
Mantri et al. have shown that the active site of this enzyme is
not conducive to arginine demethylation [27,99,100]. Other
studies by Webby et al. have shown that JMJD6 functions
rather as a lysine hydroxylase and they were unable to detect
any demethylation on H3R2me2 or H4R3me2 peptides in vitro
[101,102]. Ultimately, there are conflicting reports about the
true demethylase nature of JMJD6 [103]. The crossover
between lysine demethylation and arginine demethylation
led to continued work within the JmjC oxygenase family.
Recently it was shown by Walport et al. that lysine demethy-
lases KDM3A, KDM4E, and KDM5C also exert similar functions
for mono as well as asymmetrically and symmetrically
dimethylated peptides [104]. The dual functionality of these
enzymes alludes to a unique interplay between lysine and
arginine methylation and supports the role of these marks in
histone crosstalk. As these JmjC enzymes favor methylated
lysine substrates, further exploration into their role in vivo
and the identification of a sole arginine demethylase is
imperative [91].
2.5 Consequences of arginine methylation
Before specific instances of arginine methylation are high-
lighted in a later section, it is important to give a general
overview of the broad consequences of arginine methylation.
One significant outcome of arginine methylation is its
effect on histone crosstalk. Methylation of arginine residues
by PRMTs directly prevents the binding of other epigenetic
writers. For example, methylation of H3R2me2a by PRMT6
directly prevents methylation of H3K4me3 by the mixed-line-
age leukemia 1 (MLL1) complex, thus preventing further tran-
scription of MLL1 target genes [50,105,106]. As previously
discussed, arginine methylation can be mutually exclusive to
other PTMs other than lysine methylation, including lysine
acetylation as well as arginine citrullination. Additionally, bind-
ing of epigenetic readers containing PHD, Chromo, Tudor, and
WD40 domains is also affected [27,105,106].
Conversely, arginine dimethylation can facilitate differential
recruitment of effector molecules depending on the symme-
try. For example, the PHD domain of the de novo DNA methyl-
transferase DNMT3A has been shown to bind to the PRMT5-
specific symmetric H4R3me2s mark. Binding of this enzyme
results in DNA methylation, gene silencing, and further illus-
trates the fact that H4R3me2s is mark that promotes transcrip-
tional silencing and is thus epigenetically repressive [107].
With a few exceptions, asymmetric marks, on the other hand,
generally lead to gene activation. These marks represent the
majority of those made by the PRMT family and result in the
recruitment of complexes that open chromatin and facilitate
transcription of target genes. It is through this differential
recruitment of activating or repressive complexes that PRMTs
are able to directly alter gene transcription.
Finally, arginine methylation is a PTM that extends to non-
histone proteins as well. Like other PTMs, changes in methyla-
tion can alter interactions with binding partners, targeted
substrates, and overall protein stability. Under normal cell
physiological conditions, PRMTs operate in a tightly controlled
fashion to direct essential cellular processes. However, under
malignant conditions, these enzymes may become dysregu-
lated and alter the epigenetic landscape and proteome to
drive cell growth and survival.
3. Arginine methylation and cancer
Dysregulated PRMT expression has been documented in a wide
variety of solid and hematological malignancies. Most often,
PRMT expression is upregulated in cancer and research has
shown that a number of the enzymes in this family contribute
to oncogenesis. Here, we highlight key members of this family,
both type I and type II, that have been shown to play an integral
role in oncogenesis and maintenance of the malignant pheno-
type of both mature and stem-cell components of tumors.
3.1 PRMT1
The overexpression or aberrant splicing of PRMT1 has been
found in breast, prostate, lung, colon, and bladder cancers as
well as leukemia. The transcriptionally activating epigenetic
mark catalyzed by PRMT1 has been correlated with clinical
features including tumor grade and overall prognosis in pri-
mary and refractory solid tumors [108–111]. Recently, PRMT1
was shown to promote transcriptional activation of zinc finger
E-box-binding homeobox 1, a key regulator of epithelial–
mesenchymal transition in breast cancer cells [112].
Methylation of this promoter induces migration and invasion
of these cells as well as triggering a stem-cell-like state [112].
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The role of PRMT1 in cancer is not limited to epigenetic
regulation. It has been shown that the interaction with non-
histone substrates plays an important role as well. The ability
of PRMT1 to regulate signaling pathways such as the ER and
promote cell proliferation is potentially an important way that
this methyltransferase promotes tumorigenesis. It was
reported that the PRMT1 directly methylates ER within the
DNA binding domain in MCF7 breast cancer cells, localizing
it exclusively to the cytoplasm, and facilitating assembly of the
focal adhesion kinase and tyrosine kinase Src. This association
leads to activation of serine/threonine-protein kinase AKT and
ultimately results in enhanced cell proliferation and survival
[113,114]. Additionally, PRMT1 can act directly on substrates of
AKT such as forkhead box protein O1 and BCL-2 antagonist of
cell death. By methylating residues within an RxRxxS/T motif,
PRMT1 acts to directly prevent phosphorylation by AKT on
both substrates, suggesting an inhibitory role of PRMT1
methylation against AKT phosphorylation [115,116].
In other work, PRMT1 has been implicated as a driver of
acute myeloid leukemia (AML) development. By direct inter-
action with the MLL-EEN fusion protein, PRMT1 catalyzes aber-
rant methylation at target loci and enhances genes associated
with hematopoietic potential and promotes survival of leuke-
mia cells [117]. PRMT1 has also been shown to directly interact
with and promote transcriptional activation of the AML1-ETO
fusion gene to promote cell growth and survival [118]. Finally,
PRMT1 has been shown to bind lysine demethylase KDM4C
and facilitate epigenetic reprogramming to drive transforma-
tion of cells [119].
Methylation of DNA repair proteins 53BP1 and MRE11 by
PRMT1 helps facilitate localization and regulate exonuclease
activity, respectively, and is required for DNA damage check-
point control [120,121]. In addition, PRMT1 has been shown to
associate with telomeric repeat-binding factor 2 or TRF2, part
of a larger shelterin complex that maintains telomere length,
helps to recruit telomerase, promote the formation of the
t-loop, and protects telomeres from being recognized as
DNA damage [122–125]. Mitchell et al. have shown that TRF2
interacts with and is methylated by PRMT1 [122]. Furthermore,
knockdown of PRMT1 promotes telomerase shortening in
cancer cells [122]. It is possible that this is a result of the
negative feedback loop existing to stabilize telomere length
in cancer cells[126]. Alternatively, given its role in telomere
protection and regulation of the DNA repair pathway, inhibi-
tion of this enzyme may promote the accumulation of geno-
mic damage within the cell [56,122]. Despite this, mounting
evidence of the role of PRMT1 in cancer suggest that it could
be a promising target for inhibition in experimental treatment
of both solid and hematological malignancies.
3.2 CARM1, also known as PRMT4
In addition to controlling a number of normal cellular pro-
cesses, CARM1 expression is elevated in androgen-dependent
and -independent prostate cancers as well as aggressive
breast cancer [127–130]. Several studies have shown the abil-
ity of CARM1 to regulate the retinoblastoma protein (Rb)/E2F1
axis in breast cancer. CARM1 has been shown to enhance
activity and stability of the steroid receptor coactivator AIB1
through asymmetric methylation of arginine residues in the
C-terminal affecting both stability and activity [131]. Notably,
AIB1 is amplified in ovarian and overexpressed in ovarian and
breast cancer cells [132]. Additionally, the AIB1/CARM1 inter-
action is required for estrogen-induced CARM1 recruitment to
ER-promoters [131,133]. Furthermore, this interaction is neces-
sary for driving the production of E2F1 and its target genes,
driving cellular proliferation [134]. In addition to directly
affecting E2F, CARM1 can negatively regulate by methylating
at R7878, which affects its ability to be phosphorylated, bind
to E2F1, ultimately impairing cell cycle regulation and ablating
the tumor suppressive activity of Rb [135]. Recently, CARM1
was shown to methylate the RNA polymerase mediator com-
plex subunit MED12. Building on previous research, it was
shown that methylation of MED12 enhances sensitivity of
cancer cells to chemoresistance in both solid and hematolo-
gical malignancies [136,137].
Furthermore, CARM1 was shown to specifically methylate
BAF155, a core member of the SWI/SNF nucleosome remodel-
ing complex that has been identified as a tumor suppressor
gene in multiple solid tumor cell lines [138,139]. BAF155
methylation by CARM1 in breast cancer cell lines was shown
to affect the distribution of BAF155 binding to chromatin sites
as identified by a chromatin immunoprecipitation sequencing
approach and to correlate with enriched association of BAF155
with promoters of c-Myc pathway genes [138]. Expression of
wildtype BAF155 in a mouse breast cancer model was asso-
ciated with downregulation of metastasis repressor genes
CDH11 and KISS1R and downregulation of metastasis-promot-
ing genes CCL7, CDH6, COL4A2, CXCL12, MMP13, and MYCL,
compared with expression of a mutated version of BAF155
R1064K that is unable to be methylated. Interestingly, immu-
nohistochemistry analyses showed that methylated BAF155
levels correlated with elevation of CARM1 protein levels in
breast cancer tissues. Notably, long-term follow-up and multi-
variate analyses performed using the Cox proportional hazards
model showed that tumors containing methylated BAF155
were more likely to recur with (recurrence hazard 1.789) com-
pared with tumors that did not show methylated
BAF155 [138].
Finally, CARM1 demonstrated additional implications of
PRMTs in histone crosstalk. It has been shown that CARM1
can directly methylate histone acetyltransferases CREB-binding
protein (CBP) and p300, affecting both auto-acetylation and
activity [140]. For example, CARM1 methylation of CBP has
been shown to facilitate its interaction with glucocorticoid
receptor interacting protein 1 (GRIP1), and steroid hormone-
dependent transcriptional activation [141]. Methylation of
p300, on the other hand, prevents binding to GRIP1 [142].
Interestingly, it has been shown that CBP is differentially
recruited to estrogen-regulated genes dependent upon its
methylation status [140].
3.3 PRMT5
PRMT5 is a type II PRMT believed to largely function as tran-
scriptional repressor. Overexpression of PRMT5 has been
described in numerous aggressive malignancies including
glioblastoma, melanoma, ovarian, lung, colon, gastric, bladder,
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germ cell, and several lymphomas [14,70,143–153]. This
impaired regulation has been linked to loss of control of the
miR92b and miR96 axis, as well as transcriptionally through
nuclear transcription factor Y and transforming growth factor
beta (TGF-β) stimulation [152–154].
While studies continue to elucidate the mechanism behind
PRMT5 upregulation in cancer, additional work strives to
describe modifications of PRMT5 and associated proteins
that affect its function. The interaction between PRMT5 and
JAK2 has recently been further defined. Patients with myelo-
proliferative disorders express the constitutively active JAK2
mutant JAK2 V617F and demonstrate an increased interaction
and subsequent phosphorylation of PRMT5 [74]. This PTM of
PRMT5 decreases its methyltransferase activity and prevents
its interaction with cofactor ME50, resulting in reduced enzy-
matic activity of PRMT5. Ultimately, PRMT5 knockdown in
human CD34+ cells leads to cellular proliferation and expan-
sion as well as erythroid progenitor differentiation, which in
turn suggests that PRMT5 phosphorylation by JAK2 V617F
contributes to myeloproliferation induced by mutant
JAK2 [74].
Additional modifications affect PRMT5 activity. Aggarwal
et al. show that cyclin D1-CDK4 phosphorylates MEP50, result-
ing in the increased activity of PRMT5 [67]. This same study
demonstrated that increased PRMT5 activity results in silen-
cing of the expression of CUL4A/CUL4B ubiquitin ligases, pre-
venting the degradation of DNA replication factor CDT1 and
allowing for initiation of DNA replication, activation of DNA
damage checkpoints, and potential for malignant transforma-
tion [67].
The physiological consequences of PRMT5 expression in
cancer have been explored in a number of malignancies.
Overexpression of PRMT5 results in the silencing of a wide
variety of tumor suppressor genes including ST7 and NM23
and regulatory genes resulting in cellular hyperproliferation
[62]. Additionally, PRMT5 has been shown to directly methylate
several transcription factors including p53, E2F1, HOXA9, as well
as NF-κB [66,155–157]. Most notably, the repression of TP53 and
E2F1 further perpetuates the role of PRMT5 in cancer by allow-
ing this methyltransferase to control growth inhibition, cell
cycle arrest, and cell death. Specifically in glioblastoma,
PRMT5 knockdown results in arrested cell growth, decreased
cell migration, restoration of tumor suppressor genes, and cas-
pase-dependent apoptosis in fully differentiated glioblastoma
cells, while in undifferentiated neurospheres it leads to hypo-
phosphorylation of retinoblastoma, resulting in cellular senes-
cence [143,158]. The ability of PRMT5 to regulate both mature
and immature cell types is not unique to glioblastoma. In
chronic myeloid leukemia, imatinib-insensitive leukemia stem
cells rely on PRMT5 for self-renewal and are sensitive to PRMT5
knockdown or treatment with a PRMT5 inhibitor [159]. Finally,
PRMT5 was shown to work in concert with key oncogenic
drivers including cyclin D1, c-Myc, NOTCH1, and MLL-AF9 in
several lymphoma/leukemias, acting as a key point of conver-
gence during lymphomagenesis [69].
Recently, investigations have started to explore the
dynamics of the PRMT5-driven methylation mark. Initially this
characterized as a repressive mark, but several groups are now
showing that PRMT5 activates distinct subsets of genes.
Tarighat et al. demonstrated that PRMT5 activated SP-1 tran-
scription factor and as a result increases the expression of
FLT3 in AML cells both in vitro and in vivo [65]. Additionally,
in lung adenocarcinoma, PRMT5 was shown to activate genes
controlling TGF-β-induced epithelial-to-mesenchymal transi-
tion [153].
4. Development of selective drugs to inhibit PRMT
enzyme activity
Because of the crucial roles that PRMTs play in cancer and
other disease states, selective inhibitors are in high demand,
not only for enzyme activity inhibition but also for usage as
chemical probes to facilitate basic research exploring biologi-
cal regulatory mechanisms. Advances in X-ray crystallography
have expedited exploration of protein structures at the atomic
level, providing vast amounts of information to aid in devel-
opment of selective pharmacological inhibitors.
4.1 PRMT structures and the active site
The first PRMT crystal structure (rPRMT3 conserved core, pro-
tein data bank (PDB) ID: 1F3L) was published in 2000 by
Cheng et al. [160]. Over the past decade, crystal structures of
many PRMTs (Table 2) have been solved alone or together
with cofactor and substrates, providing insights into their
methyltransferase activity. Most of the structures were
obtained by co-crystallization of PRMTs with one or more
ligands (i.e. cofactors, cofactor analogs, histone peptide
Table 2. PRMT crystal structures.
Isoform PDB ID
PRMT1 1ORIa, 1OR8a,b, 1ORHa, 3Q7Ea
PRMT2 N/A
PRMT3 1FL3a, 1WIRc,d, 2FYTa, 3SMQc, 4HSGc, 4QQNc, 4RYLc
PRMT4 (CARM1) 2OQB, 3B3Fa, 3B3G, 3B3Jc, 4IKPa, 5U4Xc
PRMT5 3UA3a, 3UA4, 4G56a, 4GQBa,b,c, 4X60a,c, 4X61a,c, 4X63a,c, 5EMJa,c, 5EMKa,c, 5EMLa,c, 5EMMa,c, 5FA5b,c, 5C9Za
PRMT6 4HC4a, 4LWO, 4LWPa, 4QQKa, 4CO3a, 4CO4a, 4CO5a, 4CO6, 4CO7, 4CO8, 4QPPa, 4Y2Ha,c, 4Y30a,c, 5E8Ra, 5EGSa,c, 5HZMa,c, 5WCFc
PRMT7 3WSTa, 4C4Aa,c, 3X0Da, 4M36, 4W37a, 4M38a,b
PRMT8 4X41a, 5DSTa
PRMT9 N/A
aStructure contains either SAH or cofactor analog.
bStructure contains a peptide substrate.
cStructure contains an inhibitor or other interacting partners.
dStructure solved by solution.
PRMT: protein arginine methyltransferases; CARM1: co-activator-associated arginine methyltransferase 1; NMR: Nuclear Magnetic Resonance.
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substrates, or small molecule inhibitors), suggesting that
ligand binding stabilizes the protein conformation [161].
Visual representations of the PRMT crystal structures and the
conserved catalytic core are shown in Figure 2.
The nine human PRMTs are proposed to share a conserved
core, which includes a Rossman fold for cofactor binding and a
β-barrel for substrate binding, with the active site located at
the fold/barrel interface [162]. Some PRMTs contain domains
that facilitate protein–protein interactions, as shown in
Figure 1. Evidence shows that these unique domains are
responsible for recruiting other proteins, forming oligomers
or taking part in substrate binding, regulating the PRMT
enzyme activity levels [163,164].
4.2 Catalytic activity of PRMTs
Examples of select crystal structures of PRMTs and a detailed
view of the human PRMT5 active site are shown in Figure 2.
The positively charged methyl-accepting arginine residue side
chain is inserted into a negatively charged pocket generated
by two conserved glutamate residues, referred to as a ‘double
E’ hairpin loop (Glu-X8-Glu; known as E144-E153 in PRMT1,
E435-E444 in PRMT5, and E172-E181 in PRMT7), with the help
of ‘THW’ loop (known as Thr–His–Trp in PRMT1, Phe–Ser–Trp
in PRMT5, and Met–Gln–Trp in PRMT7). The interaction of
substrate arginine residues with the ‘double E’ loop redistri-
butes the positive charge on the guanidino group toward one
amino group, while leaving a lone pair of electrons on the
other amino group to attack the cationic methyl-sulfonium
moiety of SAM in an nucleophilic substitution (bi-molecular)
or SN2-like mechanism [162,165]. The addition of methyl
groups to an arginine residue changes its shape and bulkiness;
however, methylation does not neutralize the cationic charge
of an arginine residue within a substrate protein [17,20].
Structural alignments of known type I, II, and III PRMTs
show that the geometries of the active sites are highly con-
served within each PRMT enzyme type. However, the shape
of the pocket that binds the guanidino group varies in some
of the isoforms and is believed to play a role in product
specificity of each isoform [166–168]. It has been demon-
strated that both ‘double E’ loop that is assigned to subre-
gion A and ‘THW’ loop assigned to subregion B are involved
in generating product specificity [168]. A structural model
proposed by Jain et al. highlighted residues that are critical to
the methylation reaction and could potentially account for
differential enzymatic activity of specific PRMT type I, II, or III
enzymes (Figure 3) [168] . Subregions A and B seem to
possess varying degrees of special restriction. For example,
type III enzyme PRMT7 contains two restricted subregions A
and B, which might be the key feature for limiting activity to
monomethylation [168].
Additional crucial residues have been identified within the
active site of PRMTs through site-directed mutagenesis. These
residues are believed to play a key role in the methylation
process itself as well as help determine product specificity. For
example, alteration ofMet48 in rat PRMT1, a residue conserved in
the αY helix of many PRMTs, to Phe led to the production of
SDMA along with ADMA and MMA [168]. Site-directed
Figure 3. PRMT active sites display distinct spatial architectures. The active site of any PRMT can be roughly divided into two subregions: left (subregion A, colored
in orange) or right (subregion B, colored in blue) side of the substrate arginine residue. Specifically, type I PRMTs contain a spatially restricted subregion A and an
open subregion B, while type II PRMTs contain an open subregion A and a restricted subregion B. Type III contains two restrained subregions.
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mutagenesis studies have also shown Phe379 in Caenorhabditis
elegans and Phe327 in human PRMT5 to be critical residues
specific for generating SDMA [60,169].
Recently, Morales et al. proposed a catalytic mechanism for
PRMT enzymes [166]. A suggested catalytic mechanism for
type II PRMT dimethylation is proposed. Kinetic studies have
shown that PRMT5 exhibits a distributive methylation
mechanism where MMA is released before dimethylation
occurs [170,171]. When the MMA substrate returns to the
active site, it is reoriented by Phe327 through a cation–pi
interaction between the aromatic ring of Phe327 and the
positively charged monomethylated guanidyl group, thus pro-
moting orientation of arginine to promote generation of
SDMA. Note that the final product is also restrained by the
distinct spatial architecture of type II PRMTs in producing
SDMA rather than ADMA.
4.3 PRMT inhibitors
Based on the knowledge accumulated by the structure and
function of PRMT enzymes, significant attention has been
directed at designing potent and selective pharmacological
inhibitors of this enzyme family [172]. Thus far, specific inhibi-
tors for PRMT1, 3, 4, 5, and 6 have been developed and several
micromolar or nanomolar inhibitors have been obtained for
key cancer-related PRMT enzymes such as PRMT1, CARM1, and
PRMT5. A comprehensive and detailed review on PRMT-speci-
fic small molecule inhibitors was published recently by Hu
et al. [172]. Furthermore, a summary of PRMT inhibitors used
in preclinical testing is provided in Table 3, and chemical
structures of inhibitor compounds are shown in Figure 4.
The earliest PRMT inhibitors reported are cofactor (SAM)
mimics, such as compounds 1 (SAH) and compound 2 (sine-
fungin) [173,174] (Figure 4). These small molecules can inhibit
the activity of SAM-dependent methyltransferases by compet-
ing with SAM binding [163]. In 2004, Cheng et al. identified the
first set of small molecule inhibitors targeting PRMTs, repre-
sented by compound 3 (AMI-1), via a high-throughput screen-
ing of a diverse 9000-compound library [175]. However, many
of these early-stage molecules are promiscuous PRMT inhibi-
tors and lack both specificity and potency. An important goal
in the campaign of PRMT drug discovery is to develop effec-
tive lead compounds that are highly specific for particular
isoforms of each enzyme [172]. Structural studies show that
active sites of methyltransferases bear different degrees of
plasticity and structural uniqueness; thus, it is crucial to incor-
porate the protein structural information when developing
specific PRMT inhibitors [164].
Computation-based methods are widely used in modern
drug discovery. Progress has been made in PRMT enzyme
preliminary hit identification, including structure-based,
ligand/pharmacophore-based, and fragment-based virtual
screening techniques [163]. These approaches are favor-
able, particularly at early stages of development due to
improved efficiency at all levels (time, labor, cost).
Traditional medicinal chemistry strategies, such as the ana-
lysis of structure–activity relationship (SAR), are often
applied during the lead optimization phase as well. With
the help of co-crystallization methods, homology model-
ing, molecular docking (MD), and MD simulation, further
lead optimization or rational design has become an attrac-
tive way to develop inhibitors with desired properties. It is
worthwhile to note that a cutting-edge computational
method called multiple ligand simultaneous docking has
been used to develop the first-in-class PRMT5 inhibitor
HLCL-61 [65]. Chemical structures of several significant
PRMT inhibitors are shown in Figure 4 and reviewed else-
where [163,172].
4.3.1 PRMT1 inhibitors
Compounds 4–6 depicted in Figure 4 are examples of PRMT1-
specific inhibitors. Compound 4 is an early-stage inhibitor
found from a virtual screening on the NCI diversity library of
1990 compounds based on a homology-modeled PRMT1
structure exhibiting an IC50 of 1.7 μM in enzyme assays [176].
Yan et al. successfully described carbocyanine compound (5)
series and diamidine compound (6) series with adequate
potency and much higher specificity toward other PRMT
Table 3. Preclinical development of PRMT inhibitors.
PRMT target Drug Preclinical testing
PRMT1 Allantodapsone
E84
DB75
Breast cancer
Erythrocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia
Chronic myeloid leukemia, acute promyelocytic leukemia, acute myeloid leukemia, T cell leukemia, erythrocytic leukemia
PRMT3 7
SGC707
Adenocarcinoma
PRMT4/CARM1 CMPD-1
CMPD-2
SGC2085
TP-064
MS049
TBBD
Non-small cell lung carcinoma
PRMT5 CMP5
EPZ015666
LLY283
Glioblastoma
Epstein-Barr virus-positive non-Hodgkin lymphoma
Mantle cell lymphoma
PRMT6 EPZ020411
GMS
MS049
MS023
Skin melanoma
Breast cancer
PRMT7 DS-437 Breast cancer
PRMT: protein arginine methyltransferases.
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isoforms [177,178]. However, the absence of co-crystal struc-
tures for generating PRMT1-specific inhibitors will make vali-
dation and further development more of a challenge.
4.3.2 PRMT3 inhibitors
Compound 7 (Figure 4), the first described specific inhibitor
for PRMT3, was discovered by screening a 16,000-compound
diverse library and is demonstrated to be an allosteric inhibitor
bound into the dimer interface [179]. Compound 8 (Figure 4)
was developed based on compound 7 by the same research
group and found to exhibit improved cellular activity, potency
(IC50 0.03 μM) and outstanding selectivity [180]. Co-crystal
structure of PRMT3-compound 8 complex is presented in
Figure 5(a).
4.3.3 CARM1 inhibitors
CARM1 inhibitor compounds 9 and 10 are screened out as
pyrazole (9) and benzo[d]imidazole (10) inhibitors, respec-
tively, with high potency (IC50 = 0.03 μM) and satisfactory
selectivity (Figure 4) [181]. According to the co-crystal struc-
tures obtained, they both bind to the substrate arginine bind-
ing pocket; in addition, cofactor binding is a prerequisite for
the binding of inhibitor [172]. Ternary structure of CARM1-
SAH-compound 9 complex is shown in Figure 5(b). In 2016,
a potent inhibitor compound, SGC2085 (compound 11), was
identified by virtual screening and two rounds of structure-
based optimization (Figure 4) [182]. This CARM1 inhibitor
showed substantially improved potency and selectivity over
other PRMTs with an IC50 of 50 nM. Compound 12 or TP-064
was developed as the first potent, selective and cell active
chemical probe for CARM1 with IC50 < 10 nM for methylation
of H3 (1–25) [183]. The reported crystal structure (PDB: 5U4X)
of CARM1 in complex with SAH and TP-064 shows this mole-
cule to be a substrate-competitive inhibitor.
4.3.4 PRMT5 inhibitors
PRMT5 is the major type II enzyme and also an important
therapeutic cancer target. However, very few inhibitors have
been reported for PRMT5 so far. In 2015, compound 13 (CMP5)
(Figure 4), the first PRMT5 selective inhibitor described, was
discovered during a virtual screen utilizing a computational
PRMT5 homology model [14]. In the same year, the research
group at Epizyme, Inc. reported a screened-out inhibitor called
EPZ015666 (compound 14) (Figure 4) [15]. This molecule
shows outstanding selectivity to PRMT5 compared to the
other PRMTs and a much higher potency (IC50 = 0.022 μM)
than compound 13. Enzymatic and biochemical studies show
that compound 14 acts as a substrate competitor, which is
further confirmed by co-crystal structure of PRMT5:MEP50-
SAM-compound 14. Detailed active site structure is illustrated
in Figure 5(c). Note that the cation–pi interaction between the
ligand and enzyme is critical in its enzyme selective inhibition.
Similar to the CARM1-compound 9 complex, the binding of
the cofactor SAM is a prerequisite for the inhibition activity.
Recent studies indicated an enhanced dependency of
methylthioadenosine phosphorylase (MTAP) deletion cancer cells
on PRMT5 [184–186]. MTAP-deleted cells have reduced PRMT5
methylation activity and increased sensitivity to PRMT5 depletion
because of the accumulation of the metabolite methylthioadeno-
sine (MTA), found to be a PRMT5 self-inhibitor as a cofactor analog
Figure 4. Examples of reported PRMT inhibitors.
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[184]. It should be noted that excess MTA is reported to increase
the IC50 of EPZ015666 by an order of magnitude in assays of
PRMT5 activity [185]. Based on mechanistic insights, it is possible
that the reported SAM-cooperative mechanism of action of
EPZ015666 limits its inhibition of PRMT5 in the setting of excess
MTA, and the reduced SAM binding further tilts the equilibrium
between the active PRMT5:SAM and the inactive PRMT5:MTA
complexes toward the inactive form [184,185]. Thus, inhibitors
that mimic the mode of action of cofactor (e.g. SAM/MTA-compe-
titors) or MTA-cooperators will be useful to pharmacological
exploitation of PRMT5-targeted therapeutics [185]. Using this strat-
egy, the first potent and selective SAM-competitive chemical
probe for PRMT5, LLY-283 (compound 15, Figure 4) was identified.
It is a nucleoside analog with IC50 = 20 nM for methylation of an
H4R3-derived peptide substrate that exhibits potent inhibition in
cellular methylation assays [187].
4.3.5 PRMT6 inhibitors
Based on the work on type I inhibitors, structure optimization was
performed to obtain inhibitors (e.g. compound 16) with high
potency (IC50 = 10 nM) as well as moderate selectivity (~12-fold)
for PRMT6 (Figure 4) [188]. The co-crystal structure of PRMT6-SAH-
compound 16 shown in Figure 5(d) reveals that the inhibitor
occupies the arginine binding site. A bisubstrate inhibitor called
6′-methyleneamine sinefungin (GMS or compound 17) was dis-
covered by Wu et al. in 2016 (Figure 4) [189]. GMS is an analog of
sinefungin (compound 2) with significantly increased inhibition
activity than other cofactor-competitive inhibitors. This compound
can occupy both the substrate arginine binding site (PDB: 4QQK)
and cofactor binding pockets. In addition, a dual inhibitor of both
CARM1 and PRMT6 called MS049 (compound 18) was developed
through SAR studies based on their previously designed potent,
selective inhibitor of type I PRMTs inhibitor MS023 (compound 19,
Figure 4) [190,191].
4.3.6 PRMT7 inhibitors
Compound 20 is a rationally designed molecule based on the
structure of PRMT5 that was ultimately found to be a potent
PRMT5/PRMT7 dual inhibitor (IC50 = 6 nM for both enzymes)
while inactive on other PRMTs (Figure 4) [192]. Members of
this set of compounds are considered to be bi-substrate inhi-
bitors that combine structural features from both substrate
and cofactor.
Some PRMT inhibitors are found to possess capability of
binding to the histone tail peptides [172]. Compound 21
(known as allagic acid or TBBD) was found to be a CARM1
inhibitor (IC50 = 25 μM), which specifically inhibited methy-
lation of H3R17 (Figure 4) [193]. Isothermal titration colori-
metry assays showed direct binding between histone
substrate and TBBD. There are also peptide inhibitors
reported [194]. However, the limitation of peptide inhibi-
tion is its low stability in vivo and poor cell membrane
penetration [163].
Small molecule inhibitors remain the priority for PRMT
drug discovery. Despite continued efforts in inhibitor
development, potency and attractive PK profiles remain
challenges that are currently the focus of multiple groups.
Pharmacological inhibitors of PRMT2, 8, 7, 9 enzymes have
b.a.
d.c.
Figure 5. Co-crystal structures of PRMTs and their inhibitors. (a). Allosterically bound dimer of PRMT3-compound 8 (PDB: 4RYL); (b). Active site of ternary complex
CARM1-SAH-compound 9 (PDB: 2Y1W); (c). Active site of quaternary complex PRMT5:MEP50-SAH-compound 14 (PDB: 4X61); (d). Active site of ternary complex
PRMT6-SAH-compound 16 (PDB: 4Y2H).
538 E. SMITH ET AL.
yet to be described [172]. Since the majority of the
reported PRMT inhibitors lack co-crystal structures, effort
needs to be directed at solving the structures of PRMT-
inhibitor complexes to validate proposed protein–ligand
(inhibitor) interactions and facilitate lead drug optimization
efforts.
5. Expert opinion: arginine methylation as an ideal
target for cancer therapy
The diverse role of arginine methyltransferases in a wide
variety of physiologic processes clearly illustrates the impor-
tance of this class of enzyme in coordinating orderly cellular
development and homeostasis. A growing number of reports
over the past decade have pointed toward dysregulation of
select PRMTs in driving both benign and malignant diseases.
As work in this field continues to evolve, a developing body of
evidence supports the need to design selective inhibitors to
target PRMTs.
Small molecule inhibitors against other epigenetic modi-
fiers have shown promising results and have laid important
groundwork in drug discovery for this class of enzymes.
Continued work on individual PRMT structures and the
methyltransferase enzymology itself aids in the drug develop-
ment process. As drug design advances, newer generations of
arginine methyltransferase inhibitors allow for greater specifi-
city and potency by targeting multiple regions within active
sites and domains in PRMT enzymes or partner proteins.
Generation of more sophisticated compounds through drug
design aid the production of highly specific tool compounds,
and more recently, clinical drug candidates. While early work
targeting epigenetic modifying enzymes began with inhibiting
a broad spectrum of isoenzymes, work in the PRMT field has
focused on activities of select enzymes identified as critical
drivers of disease activity.
PRMT5 has been found to play a role in numerous key
pathways that contribute toward several driver activities in
multiple malignancies including MYC, Notch, and CYCLIN D1
[69]. With this knowledge, the first clinical trial delivering
targeted therapy against an enzyme in the PRMT family
chose to focus on PRMT5 (https://clinicaltrials.gov/ct2/show/
NCT02783300) [14,67,69,143,195]. New developments in
PRMT5 biology have pointed toward specific molecular mar-
kers, like MTAP deficiency, that identify particular cancers as
ideal candidates for PRMT5 inhibitor therapy. Accumulating
evidence is pointing toward PRMT5 as an ideal therapeutic
candidate for benign (sickle cell anemia, autoimmune disease)
and malignant (glioblastoma, AML, aggressive lymphomas,
squamous cell carcinoma, and carcinomas of lung, colon,
and breast) diseases.
As we learn from preclinical and clinical studies, it will be
critical to anticipate potential toxicities when developing
PRMT-targeted strategies to treat patients with cancer. For
example, work by Liu et al. has pointed toward the relevance
of PRMT5 activity in supporting normal hematopoiesis and the
potential for myelosuppression [72–74]. The association of
PRMT enzymes with a broad array of multimeric chromatin
remodeling complexes, regulatory proteins, and the spliceo-
some highlights the need for more scientific exploration to
better define the biology and anticipate potential problems
that may be encountered with targeting these enzymes ther-
apeutically [62,66,67,195,196]. Careful pharmacokinetic and
pharmacodynamic evaluation is essential to maximize the
therapeutic impact while minimizing toxicity.
It is clear that PRMTs control numerous cellular processes
and exhibit a number of pleiotropic effects. The consequences
of inhibiting these enzymes extend beyond direct targets of
PRMTs and carries over to other modifications. The indirect
effects of PRMT inhibition become apparent as the dynamic
relationships of histone crosstalk are further explored. For
example, PRMT5 inhibition can alter PI3K/AKT, cell cycle, B
cell receptor activity, and WNT/β CATENIN pathways. Several
of these pathways have been identified as being critical to
maintenance of cancer stemness and thus hold potential for
targeting both mature tumor and cancer stem cell compart-
ments, a strategy that could lead to breakthrough advances
for malignancies such as leukemia and malignant gliomas. The
widespread effects of PRMT inhibition also provide the oppor-
tunity to use these inhibitors as part of a combination therapy
in order to achieve a greater synergistic effect while reducing
toxicity due to lower concentrations required in synergistic
interactions with other classes of drug. While this gives
potency to PRMT inhibitors, it poses a potential problem
when addressing specificity. Ultimately, the prevalence of
PRMTs in cancer and widespread influence on controlling
important cancer hallmarks points toward this class of
enzymes as attractive therapeutic targets for cancer. In con-
clusion, it is our hope that the work summarized here not only
outlines PRMT form and function but also provides the
rational for targeting this class of enzymes in specific disease
settings and gives insight into the design strategy for the next
wave of epigenetic inhibitors.
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